Impaired fasting glucose (IFG) is a fasting plasma glucose between 100 and 125 mg/dL — above the normal range but below the threshold for type 2 diabetes. It is one of three laboratory definitions of "prediabetes," alongside impaired glucose tolerance (a 2-hour post-glucose value of 140–199 mg/dL on an oral glucose tolerance test) and an A1c of 5.7–6.4%. Roughly one in three U.S. adults meets criteria for prediabetes, and the vast majority do not know it.
The reason IFG matters is not the number itself but what it signals: insulin resistance has been building for years before fasting glucose budges. By the time IFG appears, beta-cell function is already measurably reduced, intra-abdominal fat is metabolically active, and cardiovascular risk is climbing. The good news is that IFG is reversible, and the interventions that work are well-documented — the Diabetes Prevention Program (DPP) showed a 58% reduction in progression to diabetes with a structured lifestyle program and a 31% reduction with metformin. Doing nothing means that roughly 5–10% of people with prediabetes progress to type 2 diabetes each year.
The biology in plain terms
After an overnight fast, the liver releases glucose at a low steady rate to supply the brain and other obligate glucose users. Insulin secreted at low basal levels keeps that hepatic glucose output in check. As insulin resistance develops — primarily in the liver and skeletal muscle — the same amount of basal insulin no longer suppresses hepatic glucose output adequately, and fasting glucose climbs. The pancreas initially compensates by producing more insulin (hyperinsulinemia), but beta-cell capacity is finite. When compensatory insulin secretion can no longer keep up, fasting glucose rises into the IFG range and eventually into the diabetes range.
This sequence is why IFG, far from being a benign "borderline" finding, is the visible tip of a long-running metabolic process. The same insulin resistance that raises fasting glucose also raises triglycerides, lowers HDL, contributes to elevated LDL particle number, drives nonalcoholic fatty liver disease, and is closely associated with hypertension and central obesity — the constellation we call metabolic syndrome.
Who is most at risk
- BMI 25 or higher (23 or higher in Asian Americans) plus any of the following risks
- Family history of type 2 diabetes in a first-degree relative
- Black, Hispanic/Latino, American Indian, Asian American, or Pacific Islander ancestry
- History of gestational diabetes or delivery of a baby weighing more than 9 lb
- Polycystic ovary syndrome
- Hypertension
- HDL below 35 mg/dL or triglycerides above 250 mg/dL
- Cardiovascular disease, including coronary artery disease or prior stroke
- Physical inactivity
- Sleep apnea
- Long-term corticosteroid use, atypical antipsychotic use, or HIV antiretroviral therapy
Per current U.S. Preventive Services Task Force and American Diabetes Association guidance, screening is recommended starting at age 35 for all adults, and earlier in those with risk factors. Repeat screening every three years if results are normal, and annually if prediabetes is detected.
How we diagnose IFG
Three blood tests are accepted for screening and diagnosis:
- Fasting plasma glucose: normal <100 mg/dL, IFG 100–125 mg/dL, diabetes ≥126 mg/dL on two occasions
- A1c: normal <5.7%, prediabetes 5.7–6.4%, diabetes ≥6.5% on two occasions
- 2-hour oral glucose tolerance test: normal <140 mg/dL, impaired glucose tolerance 140–199 mg/dL, diabetes ≥200 mg/dL
Each test catches a slightly different population. A1c and fasting glucose disagree in roughly 10–20% of patients — A1c may be falsely low in conditions that shorten red cell lifespan (hemolysis, recent blood loss, hemoglobinopathies) and falsely high in iron deficiency. When tests disagree, we typically use both, recognize that risk is higher than either single test suggests, and act on the stricter of the two values. For more on what these tests show, see our article on understanding blood work and lab panels.
Symptoms (or the lack of them)
IFG is asymptomatic. That is precisely why screening matters — patients almost never present with symptoms attributable to elevated fasting glucose in this range. By the time classic diabetes symptoms appear — increased thirst, frequent urination, blurred vision, fatigue, slow-healing wounds — fasting glucose is usually well into the diabetes range and complications are accumulating. Acanthosis nigricans, a velvety darkening of the skin in the neck folds, armpits, or groin, is one of the few physical findings of insulin resistance and warrants metabolic screening when noted.
Lifestyle intervention — what actually works
The DPP defined the standard. The intervention arm achieved:
- 7% weight loss from baseline
- 150 minutes per week of moderate-intensity physical activity (the equivalent of brisk walking 30 minutes a day, five days a week)
- A structured behavior-change program with regular contact and goal-tracking
The result was a 58% relative reduction in progression to type 2 diabetes over three years. The CDC-recognized National Diabetes Prevention Program (National DPP) is the standardized rollout of that intervention and is increasingly covered by Medicare and commercial insurance. For most patients, this is a more effective starting point than medication.
Practical dietary approach
The dietary pattern that performs best in the trials is broadly Mediterranean: vegetables, legumes, whole grains, nuts, olive oil, fish, and modest amounts of poultry and dairy, with limited red and processed meat and limited refined carbohydrates. Specific patterns that work include:
- Replacing sugar-sweetened beverages with water, unsweetened tea, or coffee
- Eating protein at every meal to reduce glycemic excursions
- Building plates around non-starchy vegetables, with whole grains and starchy carbohydrates as a side rather than the main
- Eating most calories earlier in the day; late-night eating worsens insulin resistance
Highly restrictive diets work in the short term but rarely persist. The pattern that fits your life and culture and that you can sustain at three years is the one that matters.
Activity
Both aerobic exercise and resistance training improve insulin sensitivity, by different mechanisms. The combination is more effective than either alone. Walking after meals — even 10 minutes — produces measurable reductions in postprandial glucose excursions. Tampa Bay's warm climate makes early morning and evening exercise more sustainable than midday outdoor activity, especially in summer.
Sleep and stress
Sleep restriction and poor sleep quality independently worsen insulin sensitivity and increase appetite for high-calorie foods. Treating undiagnosed sleep apnea is a routine part of metabolic risk reduction. Chronic stress raises cortisol, which directly worsens insulin resistance — mindfulness, structured stress reduction, and adequate downtime are not optional add-ons.
Medication
Metformin is the only medication routinely considered for IFG. ADA guidance suggests considering metformin in patients with prediabetes who are under 60, have BMI 35 or higher, have a history of gestational diabetes, or have rising A1c despite a serious lifestyle attempt. Metformin reduces hepatic glucose output and modestly improves insulin sensitivity. It is generally well-tolerated; the most common side effect is gastrointestinal upset that improves with slow dose titration and use of the extended-release formulation. Vitamin B12 monitoring is appropriate for long-term users.
SGLT2 inhibitors and GLP-1 receptor agonists are not FDA-approved for prediabetes, but the cardiovascular and renal data in patients with diabetes have led some clinicians to use them earlier in selected patients with other risk factors. These decisions should be individualized and discussed.
What else needs attention
Detection of IFG is an opportunity to assess the whole metabolic picture. A reasonable initial workup includes:
- Lipid panel
- Liver function tests (to screen for fatty liver disease)
- Blood pressure measurement, ideally with a home cuff for a more accurate picture — see our guide on home blood pressure monitoring
- Albumin-to-creatinine ratio
- Sleep screening if symptoms suggest sleep apnea
For patients in the St. Petersburg area, our article on understanding your blood pressure numbers pairs well with the metabolic workup, since hypertension and IFG share risk factors and tend to travel together.
Follow-up
Annual A1c (or fasting glucose) is sufficient for most patients with stable IFG and a serious lifestyle plan. More frequent monitoring is reasonable for those with rising values, multiple risk factors, or those started on metformin. The trajectory matters more than any single number — declining values mean the strategy is working.
Take-home
IFG is a warning, not a verdict. Most patients who make meaningful changes can return their fasting glucose to normal and substantially lower their long-term risk of cardiovascular disease and complications. The hardest part is treating IFG with the seriousness it deserves before symptoms appear. If you have questions about a recent lab result, want help building a sustainable plan, or are ready to enroll in a structured prevention program, contact us or schedule a visit.